Patients with severe mitral regurgitation (MR) represent a growing population at increased risk for cardiovascular mortality and morbidity. As the age and comorbidities of severe MR patients increase, the risk of surgery also increases and there is a greater need for minimally invasive therapeutic options. Since the advent of transcatheter edge-to-edge repair (TEER), the availability for patients with severe primary MR has broadened to include those with severe secondary MR with left ventricular ejection fraction (LVEF) < 50% .